Peripherin is a biomarker of axonal damage in peripheral nervous system disease
Brain · 2023
DOI: 10.1093/brain/awad234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Stephen Keddie und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromuscular Diseases, Barts Health NHS Trust, London E1 1BB, UK. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Guillain-Barre Syndrome, Dementia, Multiple Sclerosis. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Department of Health, Association of British Neurologists and Guarantors of Brain.
Abstract (Originalsprache)
Valid, responsive blood biomarkers specific to peripheral nerve damage would improve management of peripheral nervous system (PNS) diseases. Neurofilament light chain (NfL) is sensitive for detecting axonal pathology but is not specific to PNS damage, as it is expressed throughout the PNS and CNS. Peripherin, another intermediate filament protein, is almost exclusively expressed in peripheral nerve axons. We postulated that peripherin would be a promising blood biomarker of PNS axonal damage. We demonstrated that peripherin is distributed in sciatic nerve, and to a lesser extent spinal cord tissue lysates, but not in brain or extra-neural tissues. In the spinal cord, anti-peripherin antibody bound only to the primary cells of the periphery (anterior horn cells, motor axons and primary afferent sensory axons). In vitro models of antibody-mediated axonal and demyelinating nerve injury showed marked elevation of peripherin levels only in axonal damage and only a minimal rise in demyelination. We developed an immunoassay using single molecule array technology for the detection of serum peripherin as a biomarker for PNS axonal damage. We examined longitudinal serum peripherin and NfL concentrations in individuals with Guillain-Barré syndrome (GBS, n = 45, 179 time points), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP, n = 35, 70 time points), multiple sclerosis (n = 30), dementia (as non-inflammatory CNS controls, n = 30) and healthy individuals (n = 24). Peak peripherin levels were higher in GBS than all other groups (median 18.75 pg/ml versus < 6.98 pg/ml, P < 0.0001). Peak NfL was highest in GBS (median 220.8 pg/ml) and lowest in healthy controls (median 5.6 pg/ml), but NfL did not distinguish between CIDP (17.3 pg/ml), multiple sclerosis (21.5 pg/ml) and dementia (29.9 pg/ml). While peak NfL levels were higher with older age (rho = +0.39, P < 0.0001), peak peripherin levels did not vary with age. In GBS, local regression analysis of serial peripherin in the majority of individuals with three or more time points of data (16/25) displayed a rise-and-fall pattern with the highest value within the first week of initial assessment. Similar analysis of serial NfL concentrations showed a later peak at 16 days. Group analysis of serum peripherin and NfL levels in GBS and CIDP patients were not significantly associated with clinical data, but in some individuals with GBS, peripherin levels appeared to better reflect clinical outcome measure improvement. Serum peripherin is a promising new, dynamic and specific biomarker of acute PNS axonal damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuromuscular Diseases, Barts Health NHS Trust, London E1 1BB, UK.
- Department of Neuromuscular Diseases, University College London, London WC1N 3BG, UK.
- Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
- NHS Neuroimmunology and CSF Laboratory, Queen Square Institute of Neurology, London WC1N 3BG, UK.
- Department of Neuroinflammation, University College London, London WC1N 3BG, UK.
- UK Dementia Research Institute, University College London, London WC1E 6BT, UK.
ORCID-Profile: Stephen Keddie, Ryan Y S Keh, Michael K L Chou, Luuk Wieske, Axel Petzold
Förderung
- Medical Research Council
- Department of Health
- Association of British Neurologists and Guarantors of Brain
- Christos Lazari Foundation
- GBS-CIDP Foundation International
- New Zealand Neurological Foundation
- Human Frontier Science Program Long-Term Fellowship
- Wallenberg Scholar
Zitieren
APA
Keddie, S., Smyth, D., Keh, R. Y. S., Chou, M. K. L., Grant, D., Surana, S., Heslegrave, A., Zetterberg, H., Wieske, L., Michael, M., Eftimov, F., Bellanti, R., Rinaldi, S., Hart, M. S., Petzold, A., & Lunn, M. P. (2023). Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain. https://doi.org/10.1093/brain/awad234
Vancouver
Keddie S, Smyth D, Keh RYS, Chou MKL, Grant D, Surana S, et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain. 2023. doi:10.1093/brain/awad234
BibTeX
@article{Keddie2023,
author = {Keddie, Stephen and Smyth, Duncan and Keh, Ryan Y S and Chou, Michael K L and Grant, Donna and Surana, Sunaina and Heslegrave, Amanda and Zetterberg, Henrik and Wieske, Luuk and Michael, Milou and Eftimov, Filip and Bellanti, Roberto and Rinaldi, Simon and Hart, Melanie S and Petzold, Axel and Lunn, Michael P},
title = {Peripherin is a biomarker of axonal damage in peripheral nervous system disease},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awad234}
}
EUVIMED